Biotech Investment Analyst - Drug Asset & Company Assessment

• US-based biotech / healthcare investment analyst with a specialist-fund background
• Familiarity with biotech/pharma development programs
• Able to assess a drug asset and the company behind it end-to-end
• 5+ years evaluating biotech/pharma companies or assets

• →Create and critique rubrics that analyze commercial drugs and drug-development programs
• →Provide overall company and asset assessment — mechanism, clinical data, competitive position, and value drivers
• →Judge the quality of an investment-style thesis and flag weak, overconfident, or missing assumptions
• →Apply your assessment across the pilot's set of companies (~5–10)

• Duration: Approximately 10–20 hours over a 1–2 week pilot
• Remote — US-based

• Help improve expert AI evaluation of drugs and drug-development programs
• Recurring engagement for strong contributors

We consider all qualified applicants without regard to legally protected characteristics and provide reasonable accommodations upon request.